For Patients with HER2-Negative Breast Cancer, Neoadjuvant Chemotherapy Plus Bevacizumab Not Effective

the Cancer Therapy Advisor take:

According to a new study published in the journal Annals of Oncology, researchers in Germany have found that neoadjuvant treatment with anthracycline-taxane-based chemotherapy or treatment with everolimus plus paclitaxel in patients with triple negative breast cancer is not effective.

Early results of the GeparQuinto study demonstrated that neoadjuvant anthracycline-taxed based chemotherapy with bevacizumab increased pathological complete response rates in patients with triple negative breast cancer. The study also showed that patients who were non-responders to that regimen who then received everolimus plus paclitaxel had no difference in pathological complete response compared with those that received paclitaxel alone.

The long-term results show a 3-year disease-free survival rate of 80.8% and a 3-year overall survival rate of 89.7% in both groups of patients with breast cancer that received epirubin, cyclophosphamide, and docetaxel with or without bevacizumab. In addition, there was no difference in disease-free survival or overall survival rates between early non-responders that received paclitaxel with or without everolimus.

Although early results demonstrated increased pathological complete response rates in patients with breast cancer, particularly triple negative breast cancer, these long-term results to do not support the use of adding bevacizumab or everolimus.